BioAtla, Inc. (NASDAQ:BCAB) Given Average Recommendation of “Hold” by Brokerages

BioAtla, Inc. (NASDAQ:BCAB) has received a consensus rating of “Hold” from the five ratings firms that are covering the company, Marketbeat.com reports. One analyst has rated the stock with a sell rating, three have assigned a hold rating and one has assigned a buy rating to the company. The average twelve-month price objective among brokers that have issued ratings on the stock in the last year is $4.00.

A number of analysts have recently weighed in on the company. Rodman & Renshaw began coverage on shares of BioAtla in a research report on Tuesday, January 13th. They issued a “buy” rating and a $4.00 price objective for the company. Weiss Ratings restated a “sell (d-)” rating on shares of BioAtla in a research note on Friday, January 9th.

BioAtla Price Performance

BCAB stock opened at $0.21 on Friday. BioAtla has a 1-year low of $0.14 and a 1-year high of $1.43. The business has a 50-day moving average price of $0.53 and a 200 day moving average price of $0.59. The company has a market capitalization of $13.36 million, a P/E ratio of -0.18 and a beta of 1.10.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.27) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.04. On average, analysts anticipate that BioAtla will post -1.46 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Acorn Capital Advisors LLC grew its holdings in BioAtla by 19.9% during the second quarter. Acorn Capital Advisors LLC now owns 4,835,111 shares of the company’s stock worth $1,915,000 after acquiring an additional 803,065 shares during the period. Vanguard Group Inc. lifted its stake in shares of BioAtla by 9.1% in the 3rd quarter. Vanguard Group Inc. now owns 1,945,795 shares of the company’s stock valued at $1,339,000 after purchasing an additional 162,647 shares during the period. Acadian Asset Management LLC lifted its stake in shares of BioAtla by 968.9% in the 1st quarter. Acadian Asset Management LLC now owns 1,690,110 shares of the company’s stock valued at $585,000 after purchasing an additional 1,531,994 shares during the period. Millennium Management LLC purchased a new stake in BioAtla during the third quarter worth $235,000. Finally, Susquehanna International Group LLP increased its holdings in BioAtla by 237.6% in the third quarter. Susquehanna International Group LLP now owns 252,583 shares of the company’s stock valued at $174,000 after buying an additional 177,760 shares in the last quarter. 77.23% of the stock is currently owned by institutional investors and hedge funds.

BioAtla Company Profile

BioAtla, Inc (NASDAQ: BCAB) is a clinical‐stage biotechnology company focused on the development of conditionally active biologics (CABs) for oncology and other serious diseases. Utilizing its proprietary CAB technology platform, BioAtla engineers monoclonal antibodies, bispecifics and antibody-drug conjugates that remain inactive in healthy tissues but become activated in the tumor microenvironment. This targeted approach aims to improve therapeutic index by enhancing anti‐tumor potency while minimizing off-target effects and systemic toxicity.

Founded in 2012 and headquartered in San Diego, California, BioAtla has advanced multiple product candidates into clinical trials.